
Summit's Ivonescimab Decision Is Due Nov. 14: What Its Filings Show About the Cash Behind the Bet
Summit Therapeutics, which has no revenue, faces an FDA decision on ivonescimab on Nov. 14, 2026. Its SEC filings show a net loss of about $1.08 billion for FY2025 and cash that nearly quadrupled in one quarter. The AI-in-drug-discovery story around the deal is mostly forecast, and we say so.



















